KLP Kapitalforvaltning AS Has $22.81 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Key Points

• KLP Kapitalforvaltning AS increased its holdings in Edwards Lifesciences Corporation by 36.1% during Q2, owning 291,622 shares worth approximately $22.81 million.
• Several institutional investors, including Wedmont Private Capital and Farther Finance Advisors, also increased their stakes in Edwards Lifesciences, reflecting strong interest from the investment community.
• Analysts have shown optimism by raising target prices for Edwards Lifesciences, with a consensus price target of $87.06, indicating positive market sentiment about the company's future performance.

KLP Kapitalforvaltning AS boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 36.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 291,622 shares of the medical research company's stock after buying an additional 77,400 shares during the period. KLP Kapitalforvaltning AS's holdings in Edwards Lifesciences were worth $22,808,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of EW. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth $266,000. Wedmont Private Capital grew its stake in shares of Edwards Lifesciences by 18.1% in the 1st quarter. Wedmont Private Capital now owns 9,860 shares of the medical research company's stock worth $684,000 after acquiring an additional 1,512 shares in the last quarter. Farther Finance Advisors LLC grew its stake in shares of Edwards Lifesciences by 390.7% in the 1st quarter. Farther Finance Advisors LLC now owns 8,808 shares of the medical research company's stock worth $633,000 after acquiring an additional 7,013 shares in the last quarter. Pallas Capital Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth $222,000. Finally, Wealthcare Advisory Partners LLC grew its stake in shares of Edwards Lifesciences by 5.8% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 7,769 shares of the medical research company's stock worth $563,000 after acquiring an additional 429 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares of the company's stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company's stock.

Analysts Set New Price Targets

EW has been the subject of several recent analyst reports. Mizuho upped their target price on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Wall Street Zen lowered shares of Edwards Lifesciences from a "strong-buy" rating to a "buy" rating in a research note on Monday, September 29th. Wells Fargo & Company upped their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an "overweight" rating in a research note on Thursday, August 7th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Finally, BTIG Research upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a research report on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of "Moderate Buy" and a consensus target price of $87.06.

Edwards Lifesciences Price Performance

NYSE EW opened at $76.70 on Wednesday. The company has a market cap of $45.03 billion, a PE ratio of 11.04, a price-to-earnings-growth ratio of 3.68 and a beta of 1.05. Edwards Lifesciences Corporation has a 52 week low of $64.51 and a 52 week high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. The firm's 50-day simple moving average is $78.39 and its two-hundred day simple moving average is $76.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.